Valeris

Overview

Valeris is the current operating name for the combined PharmaCord + Mercalis platform, rebranded in May 2025 under Permira majority ownership. Mercalis was previously TrialCard; buyers searching TrialCard, Mercalis, PharmaCord, Policy Reporter, Policy Reporter by Mercalis, RxStudy Card, or Valeris eServices Curator are evaluating the same independent commercialization platform spanning hub services, affordability, non-commercial pharmacy, payer intelligence, field support, and market-access execution.

The Morrisville, North Carolina and Jeffersonville, Indiana operating footprint matters because it maps to both the former Mercalis payer-intelligence / affordability base and PharmaCord’s hub / non-commercial pharmacy operations. Valeris is not a distributor-owned hub stack, a narrow copay-card vendor, or only the former PharmaCord hub business. It should be evaluated as an independent integrated platform alternative to Cardinal Health Sonexus, McKesson’s access stack, EVERSANA, CareMetx, and other scaled hub / commercialization platforms. Current company materials report 500+ life sciences customers, 275+ active brands, 44M+ patients supported, and $34B+ in patient savings; treat those as scale anchors to validate in RFP, not independent performance proof.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Valeris is evaluated as an independent integrated commercialization platform spanning hub, affordability, non-commercial pharmacy, payer intelligence, field support, and market-access execution.

Capability	Buyer should compare	Valeris readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Core. PharmaCord hub-services operating base supports enrollment and case management; PatientLink digital patient support platform launched 2022.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Core. Combined hub + Policy Reporter payer intelligence supports BV and coverage triage at scale, including medical-benefit maximizer detection.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core. PharmaCord hub operations handle PA and appeals; validate brand-specific clinical-documentation depth and FRM handoff in RFP.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Core. TrialCard/Mercalis copay heritage; 9 U.S. patents covering copay accumulator/maximizer mitigation algorithms.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Core. Patient access, nursing support, and adherence run inside the integrated stack; confirm clinical-staffing model and bilingual coverage.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	Core. Multi-site non-commercial pharmacy and DTP capabilities support free-goods, bridge, quick-start, and direct-to-patient models.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Core. Policy Reporter delivers payer-policy intelligence; eServices Curator, RxStudy Card, and pharmacy workflows should be scoped separately in RFP.

Buyer Fit

• Best shortlist motion: Include Valeris when a launch wants an independent, scaled commercialization platform with hub + affordability + non-commercial pharmacy + payer intelligence + market access in one operating contract rather than stitching point solutions or accepting a distributor-owned stack.
• Best-fit buyers: Pharma manufacturers, biotech, and government program sponsors in Oncology, Rare Disease, Neurology, Immunology/Autoimmune, and Cell & Gene Therapy specialty/biologic programs.
• Less ideal fit: Programs that want a narrow point solution (copay-card only, payer-intelligence-only, hub-only) or a distributor-integrated channel handoff.
• Commercial fit: Custom/RFP; scope should specify hub, copay, non-commercial pharmacy, Policy Reporter, and market-access modules separately so pricing maps to actual usage.
• Validate before award: Confirm post-merger integration status (PharmaCord systems vs Mercalis/TrialCard systems), patent-protected copay algorithms applied to your scenarios, Policy Reporter coverage depth for your therapy class, and Fuze Health collaboration scope (April 2026) if digital pharmacy / affordability routing is in scope.

Differentiators

• Independent integrated platform: Pre-approval strategy + payer intelligence + hub + DTP non-commercial pharmacy + market access under one operating model; positioned against distributor-owned and point-solution alternatives.
• Policy Reporter payer intelligence: Real-time payer-policy data with medical-benefit maximizer detection; Turquoise Health adds a pricing-data partnership layer.
• Patent-protected copay algorithms: 9 U.S. patents on copay accumulator/maximizer mitigation — direct heritage from TrialCard’s copay franchise.
• Non-commercial pharmacy and DTP operations: Multi-site pharmacy infrastructure supports free goods, bridge, quick-start, clinical supply, and direct-to-patient models.
• Current official taxonomy: Valeris packages the business as Insights and Data, Patient Support Services, and Healthcare Provider Engagement, which is broader than classic hub outsourcing.
• Company-reported scale: Valeris reports 500+ life sciences customers, 275+ active brands, 44M+ patients supported, and $34B+ in patient savings across the combined history.

RFP Questions

• Which legacy systems (PharmaCord, Mercalis, TrialCard, Policy Reporter) run your brand today, and what is the integration timeline?
• How does Policy Reporter handle your therapy class — coverage depth, refresh cadence, payer mix?
• Which of the 9 copay accumulator/maximizer patents apply to your scenarios, and what proof points support the SLA claims?
• What median time-to-therapy, PA turnaround, and first-fill conversion metrics can be reported by brand?
• How do the non-commercial pharmacy and DTP capabilities interact with manufacturer-selected specialty pharmacy networks?
• Which RxStudy Card, eServices Curator, Curated ePA, and Policy Reporter components are included in the proposed scope, and which are separate modules?
• What launch-surge staffing, training, and bilingual coverage commitments are available in the first 90 days?
• How does the Fuze Health collaboration announced in April 2026 work in practice if digital pharmacy, eligibility, patient engagement, or affordability routing is in scope?

Recent Activity

• 2026-04: Valeris and Fuze Health announced a collaboration on a connected, performance-driven patient-access model.
• 2026-02: Valeris announced medical-benefit maximizer detection and mitigation capabilities through Patient Affordability / Policy Reporter.
• 2026-01: Reported FY2025 performance milestones, including 20+ new Patient Support Services partners and Policy Reporter growth.
• 2025-07 to 2025-09: Major C-suite builds included Peter Formisano (COO), Jodi Dickinson (Chief People Officer), Jonathan Savage (Chief Product Officer), and Manish Goel (CTO, ex-IQVIA CTO).
• 2025-05-27: Merger completed; combined PharmaCord + Mercalis company rebrands as Valeris.
• 2025-03: PharmaCord and Mercalis announce merger with Permira as majority owner.
• 2024-09: Policy Reporter / Turquoise Health strategic data partnership; Permira completes acquisition of PharmaCord.